Healthcare Providers and Services
Company Overview of Mount Sinai Hospital
Mount Sinai Hospital operates pre-eminent patient care, and research and academic health science centers. The company provides treatments in the areas of surgical oncology; fertility, pre-natal, and mother and baby care; emergency medicine and critical care; chronic diseases, such as arthritis, diabetes, heart failure, or GI disorders; health issues, including breast health, osteoporosis, and menopause; geriatric care ranging from complex medical issues to pain management and palliative care; and musculoskeletal and inflammatory bowel diseases. It also offers interpreter services, chaplaincy and spiritual care, palliative care services, nutrition and food services, and education. Mount Sinai...
Joseph and Wolf Lebovic Health Complex
600 University Avenue
Toronto, ON M5G 1X5
Founded in 1922
Key Executives for Mount Sinai Hospital
Chief Executive Officer and Director
Chief Executive Officer of Mount Sinai Medical Center and President of Mount Sinai Medical Center
Chief Nursing Executive and Senior Vice President of Patient Service
Compensation as of Fiscal Year 2012.
Mount Sinai Hospital Key Developments
Miraculins to License Additional Preeclampsia Technology from Mount Sinai Hospital
Mar 11 13
Miraculins Inc. announced its plans to add to its suite of maternal health biomarkers under license from Mount Sinai Hospital's Samuel Lunenfeld Research Institute by signing a term sheet to license methods and reagents for detecting hydroxylated Hypoxia Inducible Factor 1 alpha, a promising biomarker with potential in differentiating high and low risk pregnancies, including risk of preeclampsia. The technology is part of the pioneering research on preeclampsia and placental development being conducted by Dr. Isabella Caniggia, Senior Investigator at the Samuel Lunenfeld Research Institute, in collaboration with Dr. Martin Post, a Senior Scientist at The Hospital for Sick Children. Dr. Caniggia is also a member of Miraculins' Scientific Advisory Board and is cross-appointed at the University of Toronto as a Professor in Obstetrics and Gynecology as well as Physiology. In addition to its promise in maternal health and preeclampsia, HIF-1aOH also presents an opportunity as a cancer biomarker and of further note, the license will include unique monoclonal antibodies highly sensitive to HIF-1aOH and the exclusive rights to manufacture reagents that measure the biomarker using materials developed by Dr. Caniggia.
Mount Sinai Hospital Announces Management Changes
Jan 8 13
The Mount Sinai Medical Center announced that David L. Reich, MD, has been named Interim President of The Mount Sinai Hospital. Mr. Wayne Keathley has stepped down as President and Chief Operating Officer of The Mount Sinai Hospital to become President of Baylor College of Medicine Medical Center and Health Network in Houston, TX. Dr. Reich has been on the Appointments and Promotions Committee at Mount Sinai for the past 10 years, and has served on the Executive Committee of Mount Sinai Doctors Faculty Practice for eight years. He also serves as President of the Medical Board and has been keenly focused on strategic improvements in Hospital, School, and Faculty Practice operations over the past decade.
Mount Sinai Hospital Presents at 2011 Hospital & Healthcare I.T. Conference, Sep-28-2011
Sep 26 11
Mount Sinai Hospital Presents at 2011 Hospital & Healthcare I.T. Conference, Sep-28-2011 . Venue: Phoenix, Arizona, United States. Speakers: Susan Knox.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|